Literature DB >> 27919968

Overexpression of PBK/TOPK Contributes to Tumor Development and Poor Outcome of Esophageal Squamous Cell Carcinoma.

Takuma Ohashi1, Shuhei Komatsu2, Daisuke Ichikawa1, Mahito Miyamae1, Wataru Okajima1, Taisuke Imamura1, Jun Kiuchi1, Keiji Nishibeppu1, Toshiyuki Kosuga1, Hirotaka Konishi1, Atsushi Shiozaki1, Hitoshi Fujiwara1, Kazuma Okamoto1, Hitoshi Tsuda3,4, Eigo Otsuji1.   

Abstract

BACKGROUND: PDZ-binding kinase/T-cell-originated protein kinase (PBK/TOPK) is a serine-threonine kinase and overexpressed in various types of cancer. PBK/TOPK is associated with tumor cell development and progression through suppression of p53 function. In this study, we tested whether PBK acts as a cancer-promoting factor by being overexpressed in esophageal squamous cell carcinoma (ESCC).
MATERIALS AND METHODS: We analyzed PBK/TOPK expression in 15 ESCC cell lines, and 54 primary ESCC tumors that were curatively resected between 1994 and 2007.
RESULTS: Overexpression of the PBK/TOPK protein was detected in 93% (14/15) ESCC cell lines and 19% (10/54) primary ESCC tumor samples, and significantly correlated with macroscopic appearance and tumor depth. PBK/TOPK positivity was independently associated with worse outcome in multivariate analysis (p=0.0235, hazard ratio=3.58). Knockdown of PBK/TOPK using specific siRNAs inhibited the cell proliferation, invasion/migration of PBK/TOPK-overexpressing ESCC cell lines.
CONCLUSION: These findings suggest that PBK/TOPK plays a crucial role in tumor malignant potential through its overexpression in ESCC. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  PBK/TOPK; esophageal squamous cell carcinoma; oncogene; prognosis

Mesh:

Substances:

Year:  2016        PMID: 27919968     DOI: 10.21873/anticanres.11244

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  21 in total

1.  PBK as a Potential Biomarker Associated with Prognosis of Glioblastoma.

Authors:  Chengyuan Dong; Wenhua Fan; Sheng Fang
Journal:  J Mol Neurosci       Date:  2019-10-15       Impact factor: 3.444

2.  The differences of regulatory networks between papillary and anaplastic thyroid carcinoma: an integrative transcriptomics study.

Authors:  Zongfu Pan; Lu Li; Yangyang Qian; Xinyang Ge; Xiaoping Hu; Yiwen Zhang; Minghua Ge; Ping Huang
Journal:  Cancer Biol Ther       Date:  2020-08-23       Impact factor: 4.742

3.  Liposomal OTS964, a TOPK inhibitor: a simple method to estimate OTS964 association with liposomes that relies on enhanced OTS964 fluorescence when bound to albumin.

Authors:  Roger Gilabert-Oriol; Brent W Sutherland; Malathi Anantha; Alessia Pallaoro; Marcel B Bally
Journal:  Drug Deliv Transl Res       Date:  2019-12       Impact factor: 4.617

4.  Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC.

Authors:  Adwitiya Kar; Yu Zhang; Betelehem W Yacob; Jordan Saeed; Kenneth D Tompkins; Stacey M Bagby; Todd M Pitts; Hilary Somerset; Stephen Leong; Margaret E Wierman; Katja Kiseljak-Vassiliades
Journal:  Endocr Relat Cancer       Date:  2019-10       Impact factor: 5.678

Review 5.  The role of T-LAK cell-originated protein kinase in targeted cancer therapy.

Authors:  Lu Zhang; Fei Wang; Huijun Yi; Svetlana P Ermakova; Olesya S Malyarenko; Jianmei Mo; Yingze Huang; Qiuhong Duan; Juanjuan Xiao; Feng Zhu
Journal:  Mol Cell Biochem       Date:  2022-01-17       Impact factor: 3.396

6.  4-Hydroxytamoxifen enhances sensitivity of estrogen receptor α-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.

Authors:  Gen Wang; Sisi Qin; Jacqueline Zayas; James N Ingle; Mohan Liu; Richard M Weinshilboum; Kunwei Shen; Liewei Wang
Journal:  Breast Cancer Res Treat       Date:  2019-04-01       Impact factor: 4.872

7.  PDZ binding kinase, regulated by FoxM1, enhances malignant phenotype via activation of β-Catenin signaling in hepatocellular carcinoma.

Authors:  Yu-Feng Yang; Ying-Hua Pan; Yun Cao; Jia Fu; Xia Yang; Mei-Fang Zhang; Qiu-Hong Tian
Journal:  Oncotarget       Date:  2017-07-18

Review 8.  PBK/TOPK: An Effective Drug Target with Diverse Therapeutic Potential.

Authors:  Hai Huang; Mee-Hyun Lee; Kangdong Liu; Zigang Dong; Zeayoung Ryoo; Myoung Ok Kim
Journal:  Cancers (Basel)       Date:  2021-05-06       Impact factor: 6.639

9.  T-lymphokine-activated killer cell-originated protein kinase (TOPK) as a prognostic factor and a potential therapeutic target in glioma.

Authors:  Chuntao Quan; Juanjuan Xiao; Qiuhong Duan; Ping Yuan; Peipei Xue; Hui Lu; Meng Yan; Dongsheng Guo; Sanpeng Xu; Xiaohui Zhang; Xuan Lin; Yong Wang; Soner Dogan; Jianmin Zhang; Feng Zhu; Changshu Ke; Lin Liu
Journal:  Oncotarget       Date:  2017-12-26

Review 10.  T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics.

Authors:  Katharine J Herbert; Thomas M Ashton; Remko Prevo; Giacomo Pirovano; Geoff S Higgins
Journal:  Cell Death Dis       Date:  2018-10-24       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.